Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

FDA approves Zepbound for obstructive sleep apnea in obese individuals Discover how this weight-loss drug reduces symptoms ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) e estimate Rivian’s stock price to be $140.00 per share. Our estimated stock ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in ...

For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications.